IDEXX Laboratories, Inc. (IDXX) financial statements and ratios from SEC XBRL: revenue $4.6B (TTM), net margin 24.6%, revenue growth 9.7% YoY, P/E 36.6. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $4.30B |
| Revenue (TTM) | $4.6B |
| Net Margin | 24.6% |
| Operating Margin (TTM) | 32.0% |
| Net Debt / EBITDA | 0.2 |
| Revenue Growth (YoY) | 9.7% |
| EPS Growth (YoY) | 17.2% |
| FCF Growth (YoY) | 267.2% |
| P/E Ratio | 36.6 |
| EV / EBITDA | 26.2 |
| Price / Book | 25.85 |
| Price / Sales | 9.16 |
| FCF Yield | 2.5% |
| Altman Z-Score | 19.87 (safe) |
| Piotroski F-Score | 8/9 |
| Piotroski checks passed | 8 of 9 |
| Industry P/E (Pharmaceutical Products) | 17.1 |
| Sector P/E (Healthcare) | 21.6 |
IDXX overview · IDXX earnings · IDXX KPIs · IDXX documents · IDXX ownership · IDXX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.